Publication | Closed Access
Efficacy and tolerability of initiating, or switching to, infliximab biosimilar CT-P13 in inflammatory bowel disease (IBD): a large single-centre experience
46
Citations
15
References
2018
Year
There was no difference in the efficacy and safety of infliximab originator and CT-P13 during the first 12 months after switching.
| Year | Citations | |
|---|---|---|
Page 1
Page 1